Medica Scientia Innovation Research S.L.

• A phase 2 study to research the safety and efficacy of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with acti… Not authorised
  2024-512369-14-00 Phase II 2 countries DATOPOTAMAB DERUXTECAN; DEXCHLORPHENIRAMINE MALEATE; DIPHENHYDRAMINE HYDROCHLORI…
• PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending
  2025-524613-89-00 Phase I/II 1 country CAPECITABINE; DEXAMETHASONE SODIUM PHOSPHATE; DIPHENHYDRAMINE HYDROCHLORIDE; ERI…
• PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting
  2024-520027-88-00 Phase II 2 countries CAMIZESTRANT
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting
  2023-505661-89-00 Phase II 4 countries ABEMACICLIB; GIREDESTRANT; INAVOLISIB
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting
  2024-512360-55-00 Phase II 9 countries ABEMACICLIB; ANASTROZOLE; EXEMESTANE; FULVESTRANT; LETROZOLE; PALBOCICLIB; RIBOC…
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting
  2024-512926-27-00 Phase III 7 countries ELACESTRANT; EVEROLIMUS
• A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting
  2023-508112-35-00 Phase II 3 countries REPOTRECTINIB
• Phase II Study to Assess the Efficacy of Niraparib Rechallenge after Surgery in Ovarian Cancer Patients with Oligometastatic Progression (Th… Recruiting
  2023-508258-24-00 Phase II 1 country NIRAPARIB TOSILATE MONOHYDRATE
• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended
  2024-513511-27-00 Phase II 1 country CARBOPLATIN; PACLITAXEL; PEMBROLIZUMAB
• A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended
  2023-507306-13-00 Phase II 4 countries TRASTUZUMAB DERUXTECAN; TRASTUZUMAB, PERTUZUMAB
• Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended
  2023-506702-39-00 Phase II 2 countries TRASTUZUMAB DERUXTECAN
• PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED… Ended
  2024-512963-30-00 Phase II 1 country ERIBULIN; IZORLISIB MESILATE
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended
  2023-508738-32-00 Phase II 4 countries TRASTUZUMAB, PERTUZUMAB
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended
  2023-509923-42-00 Phase II 5 countries CARBOPLATIN; DOCETAXEL; LETROZOLE; PERTUZUMAB; TAMOXIFEN CITRATE; TRASTUZUMAB
• PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF DEBIO 0123 AND SACITUZUMAB GOVITECAN IN TNBC OR HR+/HER2- ADVANCED/ METASTATIC BREAST C… Halted
  2024-516322-60-00 Phase I/II 1 country
• A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended
  2023-503251-10-00 Phase II 2 countries PATRITUMAB DERUXTECAN
• PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended
  2023-503565-36-00 Phase II 2 countries GIREDESTRANT
• Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-N… Ended
  2024-514060-10-00 Phase II 1 country FILGRASTIM; LOPERAMIDE HYDROCHLORIDE; SACITUZUMAB GOVITECAN
• A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended
  2023-509591-42-00 Phase II 3 countries
• “A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini… Ended
  2023-508001-25-00 Phase II 3 countries LENVATINIB; PEMBROLIZUMAB
• “A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastati… Ended
  2023-509387-24-00 Phase II 1 country ENZALUTAMIDE; TALAZOPARIB
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended
  2024-511295-33-00 Phase II 1 country EXEMESTANE; FULVESTRANT; LETROZOLE; METFORMIN HYDROCHLORIDE; TAMOXIFEN; VILDAGLI…
• Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER… Ended
  2024-514999-41-00 Phase II 1 country IRINOTECAN
• A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended
  2025-521489-80-00 Phase II 1 country DOMVANALIMAB; SACITUZUMAB GOVITECAN; ZIMBERELIMAB

Showing 1–24 of 24 trials